397 related articles for article (PubMed ID: 16925756)
1. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
5. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
[TBL] [Abstract][Full Text] [Related]
6. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
[TBL] [Abstract][Full Text] [Related]
8. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.
Homma Y; Akaza H; Okada K; Yokoyama M; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 Apr; 11(4):218-24. PubMed ID: 15028100
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
11. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
12. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
13. [Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up].
Isorna Martínez de la Riva S; Belón López-Tomasety J; Marrero Domínguez R; Alvarez Cruz E; Santamaría Blanco P
Arch Esp Urol; 2004 Sep; 57(7):679-92. PubMed ID: 15536949
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: the role of hormonal therapy.
Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
17. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.
Hashine K; Numata K; Azuma K; Sumiyoshi Y; Kataoka M
Jpn J Clin Oncol; 2005 Nov; 35(11):655-9. PubMed ID: 16275680
[TBL] [Abstract][Full Text] [Related]
19. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy for locally advanced prostate cancer.
Fowler JE; Bigler SA; White PC; Duncan WL
J Urol; 2002 Aug; 168(2):546-9. PubMed ID: 12131306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]